Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valacyclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.69 |
| ▸ | PNP known ✓ | P00491 | 7/20 | 0.66 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.66 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.66 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.60 |
| ▸ | POLG | P54098 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valacyclovir SCHEMBL28846557 | 1.00 | HBB (1.00) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL725136 | 1.00 | HBB (1.00) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL27491208 | 1.00 | HBB (1.00) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL8320611 | 1.00 | HBB (1.00) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL1560193 | 1.00 | HBB (1.00) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL1697660 | 0.99 | HBB (0.98) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL5195349 | 0.99 | HBB (0.98) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL27680321 | 0.99 | HBB (0.98) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL27680319 | 0.99 | HBB (0.98) | HBBMAPK1MEN1KMT2APDE3A | |
| Valacyclovir SCHEMBL13575743 | 0.99 | MEN1 (1.00) | HBBMAPK1MEN1KMT2APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5459 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260060964-A1 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | ANTIVIRUS THERAPEUTICS (US) | 2026-03-05 | — | — | US | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4673568-A1 | MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS | Karius, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-5872123-A | Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome | LERNER A MARTIN (US) | 1999-02-16 | — | — | US | claimed |
| EP-0874631-A1 | USE OF VALACICLOVIR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF GENITAL HERPES BY A SINGLE DAILY APPLICATION | GLAXO GROUP LIMITED (GB) | 1998-11-04 | — | — | EP | claimed |
| EP-0806943-A1 | VALACICLOVIR TABLETS CONTAINING COLLOIDAL SILICON DIOXIDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-11-19 | — | — | EP | claimed |
| EP-0804436-A1 | GUANINE DERIVATIVE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-11-05 | — | — | EP | claimed |
| US-5677308-A | Method for alleviating spasmodic torticollis | LERNER A MARTIN (US) | 1997-10-14 | — | — | US | claimed |
| WO-1997025989-A1 | USE OF VALACICLOVIR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF GENITAL HERPES BY A SINGLE DAILY APPLICATION | GLAXO GROUP LIMITED (GB) | 1997-07-24 | — | — | WO | claimed |
| WO-1996022291-A1 | GUANINE DERIVATIVE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-25 | — | — | WO | claimed |
| WO-1996022082-A1 | VALACICLOVIR TABLETS CONTAINING COLLOIDAL SILICON DIOXIDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-25 | — | — | WO | claimed |
| EP-0308065-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-04 | — | — | EP | claimed |
| US-4957924-A | VIRICIDES, ACYCLOVIR GENERATION | BURROUGHS WELLCOME CO. (US) | 1990-09-18 | — | — | US | claimed |